Please login to the form below

Not currently logged in


This page shows the latest morphosys news and features for those working in and with pharma, biotech and healthcare.

Janssen’s Tremfya cleared for European use

Janssen’s Tremfya cleared for European use

Tremfya, an anti-IL-23 monoclonal antibody, was developed using MorphoSys ’HuCAL antibody library technology, allowing the German biotech to collect royalties on Tremfya sales under a multiple target deal it ... Dr Simon Moroney, chief executive officer

Latest news

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2016 Deal Watch November 2016

    acquisition - company. 125+. MorphoSys/ Leo Pharma. discovery and development of mAbs for skin diseases.

  • Pharma deals in March 2015 Pharma deals in March 2015

    In the same area is Morphosys which has been less fortunate this month because of the termination of its $818m agreement with Celgene to develop a Mab for treatment of multiple ... myeloma. Morphosys' share price fell by over 20%. This is an

  • Deal Watch table for August 2014 Deal Watch table for August 2014

    187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).

  • Pharma deals during August 2014 Pharma deals during August 2014

    These include the usual sprinkling of small molecule (Millennium/ Infinity, Hanmi/ Luye, Ziopharm/ Solasia) and antibody (Emergent/ Morphosys) approaches but also more alternative approaches as exemplified by the Gamida/ Novartis agreement.

  • Pharma deals during June 2014 Pharma deals during June 2014

    Joining the checkpoint modulator fray, Merck Serono formed a partnership with Morphosys to discover and develop antibodies against certain immune checkpoints using the Morphosys Ylanthia platform.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Quintiles Medical Communications

Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...